The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer.

abstract：BACKGROUND AND OBJECTIVES:Pathogen-derived molecules are danger signals and are able to activate innate immunity that in turn controls and regulates generation of adaptive immune responses. Mycobacterium tuberculosis heat shock protein 70 (myc HSP70) has been shown to exert a potent adjuvant effect in vaccination again...

journal_title：Haematologica

authors： Liso A,Benedetti R,Fagioli M,Mariano A,Falini B

更新日期：2005-01-01 00:00:00

abstract：:Fludarabine-cyclophosphamide-rituximab is the most efficient first-line treatment for chronic lymphocytic leukemia patients. Many dose adjustments of the original MD Anderson Cancer Center regimen have been proposed. However, whether fludarabine-cyclophosphamide-rituximab relative dose intensity may have an impact on ...

journal_title：Haematologica

authors： Bouvet E,Borel C,Obéric L,Compaci G,Cazin B,Michallet AS,Laurent G,Ysebaert L

更新日期：2013-01-01 00:00:00

abstract：:Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy. For patients with relapsed/refractory multiple myeloma, we developed a treatment schema of metronomically scheduled drug therapy. We identified 186 patients who had been treated with metronomic therapy between March 2004 and...

journal_title：Haematologica

authors： Papanikolaou X,Szymonifka J,Rosenthal A,Heuck CJ,Mitchell A,Johann D Jr,Keller J,Waheed S,Usmani SZ,Van Rhee F,Bailey C,Petty N,Hoering A,Crowley J,Barlogie B

更新日期：2013-07-01 00:00:00

abstract：:Interactions of malignant multiple myeloma (MM) plasma cells (MM-cells) with the microenvironment control MM-cell growth, survival, drug-resistance and dissemination. As in MM microvascular density increases in the bone marrow (BM), we investigated whether BM MM endothelial cells (MMECs) control disease progression vi...

journal_title：Haematologica

authors： Solimando AG,Da Vià MC,Leone P,Borrelli P,Croci GA,Tabares P,Brandl A,Di Lernia G,Bianchi FP,Tafuri S,Steinbrunn T,Balduini A,Melaccio A,De Summa S,Argentiero A,Rauert-Wunderlich H,Frassanito MA,Ditonno P,Henke E,Kl

更新日期：2020-04-30 00:00:00

abstract：:Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared with placebo (COMFORT-I) and best available therapy (COMFORT-II). We pre...

journal_title：Haematologica

authors： Vannucchi AM,Kantarjian HM,Kiladjian JJ,Gotlib J,Cervantes F,Mesa RA,Sarlis NJ,Peng W,Sandor V,Gopalakrishna P,Hmissi A,Stalbovskaya V,Gupta V,Harrison C,Verstovsek S,COMFORT Investigators.

更新日期：2015-09-01 00:00:00

abstract：:Primary vaginal non-Hodgkin lymphoma is really uncommon and may be misdiagnosed as inflammatory disease or solid cancer, so careful diagnostic procedures are needed, particularly as far as pathological and immunocytochemical evaluation is concerned. Most of these lymphomas present with follicular patterns and limited ...

journal_title：Haematologica

authors： Lonardi F,Ferrari V,Pavanato G,Bonciarelli G,Jirillo A,Balli M

更新日期：1994-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:A magnetic resonance (MR) signal shows an inverse correlation with bone marrow cellularity. In this study, we investigated the possibility of estimating the degree of bone marrow cellularity by means of this non-invasive technique. METHODS:In 25 patients with different hematological disorders ...

journal_title：Haematologica

authors： Rozman M,Mercader JM,Aguilar JL,Montserrat E,Rozman C

更新日期：1997-03-01 00:00:00

abstract：:By combining the polymerase chain reaction (PCR) of the gamma globin gene promoters with synthetic oligonucleotide analysis we have diagnosed the -196 C----T and the -117 G----A substitutions in heterozygous carriers of non deletional A gamma HPFH from two unrelated Italian families. The identification of the beta-tha...

journal_title：Haematologica

authors： Gottardi E,Alfarano A,Serra A,Sciarratta G,Bertero MT,Saglio G,Camaschella C

更新日期：1990-01-01 00:00:00

abstract：:Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are one of the most frequent chromosomal aberrations in acute myeloid leukemia. We evaluated the function of Meningioma 1 (MN1), a co-factor of HOXA9 and MEIS1, in human and murine MLL-rearranged leukemia by CRISPR-Cas9 mediated deletion of MN1. MN1 was require...

journal_title：Haematologica

authors： Sharma A,Jyotsana N,Gabdoulline R,Heckl D,Kuchenbauer F,Slany RK,Ganser A,Heuser M

更新日期：2020-05-01 00:00:00

abstract：:In the eighties there has been an enormous increase in our knowledge about erythropoietin, previously defined as "an elusive hormone". In this review we summarize the structural and molecular features, the mechanisms of production and of metabolism, the more important methods of assay, the mechanism of action and the ...

journal_title：Haematologica

authors： Liberato NL,Costa A,Barosi G

更新日期：1990-07-01 00:00:00

abstract：:Renewing interest in cancer immunotherapy reflects the excellent results that have been obtained in animal models and the promising results in early clinical trails with dendritic cell (DC) based approaches. The central role that DCs play in the initiation of an immune response raises the possibility of using them to ...

journal_title：Haematologica

authors： Di Nicola M,Lemoli RM

更新日期：2000-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Transferrin receptor (TfR) expression in erythroid cells is regulated by a number of factors, including iron status and erythropoietin (Epo) stimulation. However, the impact of these factors on reticulocyte TfR expression in vivo has never been studied. A soluble form of TfR (sTfR) is present ...

journal_title：Haematologica

authors： R'zik S,Loo M,Beguin Y

更新日期：2001-03-01 00:00:00

abstract：BACKGROUND:Immunoglobulin gene somatic hypermutation is a biologically relevant and clinically useful prognostic factor in different types of low-grade B-cell lymphomas, including chronic lymphocytic leukemia, mantle cell lymphoma and splenic marginal zone lymphoma. DESIGN AND METHODS:With the aim of identifying surro...

journal_title：Haematologica

authors： Tracey L,Aggarwal M,García-Cosio M,Villuendas R,Algara P,Sánchez-Beato M,Sánchez-Aguilera A,García JF,Rodríguez A,Camacho FI,Martínez N,Ruiz-Ballesteros E,Mollejo M,Piris MA

更新日期：2008-08-01 00:00:00

abstract：:In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After tw...

journal_title：Haematologica

authors： Palandri F,Iacobucci I,Castagnetti F,Testoni N,Poerio A,Amabile M,Breccia M,Intermesoli T,Iuliano F,Rege-Cambrin G,Tiribelli M,Miglino M,Pane F,Saglio G,Martinelli G,Rosti G,Baccarani M,GIMEMA Working Party on CML.

更新日期：2008-05-01 00:00:00

abstract：:Granulocyte transfusions are used to treat neutropenic patients with life-threatening bacterial or fungal infections that do not respond to anti-microbial drugs. Donor neutrophils that have been mobilized with granulocyte-colony stimulating factor (G-CSF) and dexamethasone are functional in terms of antibacterial acti...

journal_title：Haematologica

authors： Gazendam RP,van de Geer A,van Hamme JL,Tool AT,van Rees DJ,Aarts CE,van den Biggelaar M,van Alphen F,Verkuijlen P,Meijer AB,Janssen H,Roos D,van den Berg TK,Kuijpers TW

更新日期：2016-05-01 00:00:00

abstract：:Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (...

journal_title：Haematologica

authors： Hütter-Krönke ML,Benner A,Döhner K,Krauter J,Weber D,Moessner M,Köhne CH,Horst HA,Schmidt-Wolf IG,Rummel M,Götze K,Koller E,Petzer AL,Salwender H,Fiedler W,Kirchen H,Haase D,Kremers S,Theobald M,Matzdorff AC,Ganse

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Anaplastic lymphoma kinase (ALK) oncogenic fusion proteins, expressed in about 60% of anaplastic large cell lymphomas (ALCL), are tumor-specific molecular targets for such a malignancy. One of the promising ALK-targeted therapeutic options is cancer vaccination. In this study, we investigate w...

journal_title：Haematologica

authors： Passoni L,Gallo B,Biganzoli E,Stefanoni R,Massimino M,Di Nicola M,Gianni AM,Gambacorti-Passerini C

更新日期：2006-01-01 00:00:00

abstract：:We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patie...

journal_title：Haematologica

authors： Götze KS,Hoffmann D,Schätzl HM,Peschel C,Fend F,Decker T

更新日期：2007-09-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The efficacy and safety of added dexamethasone were assessed in patients with relapsed and/or refractory multiple myeloma who had a suboptimal response to bortezomib alone. DESIGN AND METHODS:In two previously reported, open-label, multicenter phase 2 studies, bortezomib 1.0 or 1.3 mg/m2 was ...

journal_title：Haematologica

authors： Jagannath S,Richardson PG,Barlogie B,Berenson JR,Singhal S,Irwin D,Srkalovic G,Schenkein DP,Esseltine DL,Anderson KC,SUMMIT\/CREST Investigators.

更新日期：2006-07-01 00:00:00

abstract：:Systemic anaplastic large cell lymphoma is a category of T-cell non-Hodgkin's lymphoma which can be further subdivided into two distinct entities (ALK(+) and ALK(-)) based on the presence or absence of ALK gene rearrangements. Among several pathways triggered by ALK signaling, constitutive activation of STAT3 is stric...

journal_title：Haematologica

authors： Spaccarotella E,Pellegrino E,Ferracin M,Ferreri C,Cuccuru G,Liu C,Iqbal J,Cantarella D,Taulli R,Provero P,Di Cunto F,Medico E,Negrini M,Chan WC,Inghirami G,Piva R

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Subcutaneous Ara-C plus interferon (IFN) produces more cytogenetic responses than IFN in chronic myeloid leukemia (CML) but a greater toxicity. The objective of this study was to determine the efficacy and tolerance of IFN plus oral Ara-C ocfosfate (YNK-01) in IFN-resistant CML patients. DESI...

journal_title：Haematologica

authors： Cervantes F,Sureda A,Hernández-Boluda JC,Martino R,Brunet S,Borrego D,Antich JL,Montserrat E

更新日期：2001-12-01 00:00:00

abstract：:Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatment insensitivity to FLT3 inhibitors, including sorafenib. Using a geno...

journal_title：Haematologica

authors： Damnernsawad A,Bottomly D,Kurtz SE,Eide CA,McWeeney SK,Tyner JW,Nechiporuk T

更新日期：2020-12-30 00:00:00

abstract：:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic neoplasm whose immunophenotype remains incompletely characterized, particularly in terms of distinction from reactive plasmacytoid dendritic cells (PDCs). This limitation complicates detection of low-level involvement by BPDCN as well as mini...

journal_title：Haematologica

authors： Wang W,Khoury JD,Miranda RN,Jorgensen JL,Xu J,Loghavi S,Li S,Pemmaraju N,Nguyen T,Medeiros LJ,Wang SA

更新日期：2020-04-02 00:00:00

abstract：:We report on a case of acute myeloid leukemia in a 17-year old boy affected by Shwachman Diamond syndrome (SDS). Conventional cytogenetics at diagnosis revealed an abnormal clone with complex karyotypic changes including typical myeloid aberrations, such as monosomy 5, tetrasomy of chromosome 8, trisomy 9, and deletio...

journal_title：Haematologica

authors： Spirito FR,Crescenzi B,Matteucci C,Martelli MF,Mecucci C

更新日期：2000-11-01 00:00:00

abstract：:Post-transfusion hepatitis (PTH) is a major problem in patients with acute leukemias requiring blood products during induction or consolidation therapy. In fact, PTH causes delays of chemotherapy with major violations in the timing of protocols. In order to assess the efficacy and safety of a short course of alpha-int...

journal_title：Haematologica

authors： Almasio P,Mirto S,Malleo C,Di Marco V,Caronia F,Craxi A

更新日期：1991-09-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patients affected by Hodgkin's disease (HD) in pathologic stage IA-IIA have a strong possibility of remission and long-term survival when treated with radiotherapy to extended fields. However, 20-30% of cases relapse in the five years following treatment and consequently need further therapy. T...

journal_title：Haematologica

authors： Enrici RM,Anselmo AP,Donato V,Falchetto Osti M,Santoro M,Tombolini V,Mandelli F

更新日期：1999-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Storage pool diseases (SPD) are heterogeneous disorders associated with an abnormal presence of intraplatelet granules, which cause mild to moderate bleeding diathesis. We investigated signaling through tyrosine phosphorylation of proteins occurring in platelets with total or partial absence o...

journal_title：Haematologica

authors： Arderiu G,Díaz-Ricart M,Domenech P,Escolar G,Ordinas A,Pujol-Moix N

更新日期：2002-06-01 00:00:00

abstract：:Thrombosis occurs in 20 to 30% of patients with Behçet's disease (BD), but the precise pathogenic mechanism underlying the thrombotic tendency in these patients is not well known. Venous thromboses are commonly located in the lower extremities, but right intracardiac thrombi are extremely rare. We report for the first...

journal_title：Haematologica

authors： Vayá A,Forner MJ,Estellés A,Villa P,Mira Y,Ferrando F,García Fuster JM,Oliver V,Aznar J

更新日期：2000-04-01 00:00:00

abstract：:We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61)...

journal_title：Haematologica

authors： Knop S,Straka C,Haen M,Schwedes R,Hebart H,Einsele H

更新日期：2005-09-01 00:00:00

abstract：:Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall su...

journal_title：Haematologica

authors： Dimopoulos MA,Weisel KC,Song KW,Delforge M,Karlin L,Goldschmidt H,Moreau P,Banos A,Oriol A,Garderet L,Cavo M,Ivanova V,Alegre A,Martinez-Lopez J,Chen C,Spencer A,Knop S,Bahlis NJ,Renner C,Yu X,Hong K,Sternas L,

更新日期：2015-10-01 00:00:00